IL311866B2 - Anti-TGF-beta antibodies and their use - Google Patents

Anti-TGF-beta antibodies and their use

Info

Publication number
IL311866B2
IL311866B2 IL311866A IL31186624A IL311866B2 IL 311866 B2 IL311866 B2 IL 311866B2 IL 311866 A IL311866 A IL 311866A IL 31186624 A IL31186624 A IL 31186624A IL 311866 B2 IL311866 B2 IL 311866B2
Authority
IL
Israel
Prior art keywords
tgf
beta antibodies
antibodies
beta
Prior art date
Application number
IL311866A
Other languages
English (en)
Hebrew (he)
Other versions
IL311866A (en
IL311866B1 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority claimed from PCT/IB2018/000088 external-priority patent/WO2018134681A1/en
Publication of IL311866A publication Critical patent/IL311866A/en
Publication of IL311866B1 publication Critical patent/IL311866B1/en
Publication of IL311866B2 publication Critical patent/IL311866B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL311866A 2017-01-20 2018-01-19 Anti-TGF-beta antibodies and their use IL311866B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
EP17305061 2017-01-20
PCT/IB2018/000088 WO2018134681A1 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use

Publications (3)

Publication Number Publication Date
IL311866A IL311866A (en) 2024-06-01
IL311866B1 IL311866B1 (en) 2025-11-01
IL311866B2 true IL311866B2 (en) 2026-03-01

Family

ID=61656071

Family Applications (3)

Application Number Title Priority Date Filing Date
IL311866A IL311866B2 (en) 2017-01-20 2018-01-19 Anti-TGF-beta antibodies and their use
IL268112A IL268112B2 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use
IL323799A IL323799A (en) 2017-01-20 2025-10-05 Anti-tgf-beta antibodies and their use

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL268112A IL268112B2 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use
IL323799A IL323799A (en) 2017-01-20 2025-10-05 Anti-tgf-beta antibodies and their use

Country Status (22)

Country Link
US (4) US10766955B2 (enExample)
JP (4) JP7213186B2 (enExample)
CN (2) CN110520441B8 (enExample)
AU (2) AU2018209391B2 (enExample)
BR (1) BR112019014787A2 (enExample)
CA (1) CA3050845A1 (enExample)
CL (1) CL2019002011A1 (enExample)
CO (1) CO2019008946A2 (enExample)
CR (1) CR20190375A (enExample)
DO (1) DOP2019000191A (enExample)
EC (1) ECSP19059553A (enExample)
IL (3) IL311866B2 (enExample)
MA (1) MA47311A (enExample)
MX (2) MX2019008551A (enExample)
MY (1) MY200751A (enExample)
NZ (1) NZ796440A (enExample)
PE (1) PE20200734A1 (enExample)
PH (1) PH12019501635A1 (enExample)
SG (1) SG11201906660TA (enExample)
TW (3) TWI787230B (enExample)
UY (1) UY37575A (enExample)
ZA (1) ZA201904494B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
CA3105333A1 (en) * 2018-07-10 2020-01-16 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
WO2020132647A1 (en) * 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
WO2022266510A1 (en) * 2021-06-18 2022-12-22 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
CA3227318A1 (en) 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
EP4426431A1 (en) * 2021-11-01 2024-09-11 Genzyme Corporation Treatment of osteogenesis imperfecta
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽
AU2023254108B2 (en) 2022-04-13 2026-01-29 Immunitybio, Inc. Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153435A1 (en) * 2013-03-20 2014-09-25 Genzyme Corporation Methods for treating osteogenesis imperfecta
US20150203579A1 (en) * 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20160289315A1 (en) * 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of Cancer Using Inhibitors of TGF-BETA and PD-1

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP2006523609A (ja) 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
US20060286105A1 (en) 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CA2561686C (en) * 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
CN102325795B (zh) 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013178736A1 (en) 2012-05-31 2013-12-05 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
SG10202002334PA (en) 2013-12-17 2020-05-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
MY188749A (en) 2015-04-17 2021-12-28 Bristol Myers Squibb Co Compositions comprising a combination of nivolumab and ipilimumab
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
WO2018027329A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153435A1 (en) * 2013-03-20 2014-09-25 Genzyme Corporation Methods for treating osteogenesis imperfecta
US20150203579A1 (en) * 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20160289315A1 (en) * 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of Cancer Using Inhibitors of TGF-BETA and PD-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORRIS, JOHN C., ET AL., PHASE I STUDY OF GC1008 (FRESOLIMUMAB): A HUMAN ANTI-TRANSFORMING GROWTH FACTOR-BETA (TGF?) MONOCLONAL ANTIBODY IN PATIENTS WITH ADVANCED MALIGNANT MELANOMA OR RENAL CELL CARCINOMA., 11 March 2014 (2014-03-11) *
NEWMAN, ROLAND, ET AL., MODIFICATION OF THE FC REGION OF A PRIMATIZED IGG ANTIBODY TO HUMAN CD4 RETAINS ITS ABILITY TO MODULATE CD4 RECEPTORS BUT DOES NOT DEPLETE CD4+ T CELLS IN CHIMPANZEES., 1 February 2001 (2001-02-01) *

Also Published As

Publication number Publication date
CN117417939A8 (zh) 2024-07-12
PE20200734A1 (es) 2020-07-23
IL268112A (en) 2019-09-26
CN110520441B (zh) 2023-11-14
US20220195026A1 (en) 2022-06-23
CN117417939A (zh) 2024-01-19
US12049496B2 (en) 2024-07-30
PH12019501635A1 (en) 2019-11-04
CO2019008946A2 (es) 2019-09-30
JP2023052376A (ja) 2023-04-11
DOP2019000191A (es) 2019-10-15
IL268112B2 (en) 2025-09-01
CA3050845A1 (en) 2018-07-26
US11242384B2 (en) 2022-02-08
US20200399358A1 (en) 2020-12-24
JP2020514310A (ja) 2020-05-21
ECSP19059553A (es) 2019-08-30
JP2026036696A (ja) 2026-03-05
TWI856437B (zh) 2024-09-21
AU2018209391B2 (en) 2024-08-15
UY37575A (es) 2018-10-31
IL268112B1 (en) 2025-05-01
TWI787230B (zh) 2022-12-21
AU2024264593A1 (en) 2024-12-05
SG11201906660TA (en) 2019-08-27
ZA201904494B (en) 2020-12-23
TW202506185A (zh) 2025-02-16
MA47311A (fr) 2019-11-27
MX2019008551A (es) 2020-01-27
US20250026821A1 (en) 2025-01-23
TW202313678A (zh) 2023-04-01
CN110520441A (zh) 2019-11-29
US10766955B2 (en) 2020-09-08
MY200751A (en) 2024-01-13
JP2024038040A (ja) 2024-03-19
CR20190375A (es) 2019-12-17
JP7213186B2 (ja) 2023-01-26
IL311866A (en) 2024-06-01
AU2018209391A1 (en) 2019-09-05
MX2023002588A (es) 2023-03-22
US20180244763A1 (en) 2018-08-30
IL311866B1 (en) 2025-11-01
CL2019002011A1 (es) 2019-11-22
BR112019014787A2 (pt) 2020-02-27
NZ756431A (en) 2025-03-28
JP7411832B2 (ja) 2024-01-11
TW201833135A (zh) 2018-09-16
IL323799A (en) 2025-12-01
JP7844425B2 (ja) 2026-04-13
CN110520441B8 (zh) 2024-07-09
NZ796440A (en) 2025-12-19

Similar Documents

Publication Publication Date Title
IL268112A (en) Anti-TGF-beta antibodies and their use
ZA202105676B (en) Anti-trem2 antibodies and related methods
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
IL268206A (en) Antibodies directed against bcma and their use
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL264970A (en) Anti-tim-3 antibodies and their use
IL273411A (en) Antibody against PD-L1 and its uses
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL269134A (en) Antibodies against PAR2 and their use
IL265689A (en) Antibodies against il-33 and their use
IL273157A (en) Antibodies specific to AXL and their uses
ME03525B (me) Anti-egfrviii antitijela i njihova primjena
IL272476A (en) Anti-Apelin antibodies and their uses
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
IL263242A (en) Cytosol-penetrating antibody and use thereof
IL266049A (en) Antibodies against o1 and their uses
IL274202A (en) Antibodies against Glyco-Moc1 and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
IL268568A (en) TRAILshort antibody and methods of use
IL264417A (en) Anti-o2 antibodies and their uses
SG11202003585VA (en) Anti-vista antibody and use thereof